Skip to main content

Table 2 MD Anderson Cancer Center Residual Cancer Burden Index

From: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Residual Cancer Score

N = 49*

Class I

2 (4.1%)

Class II

20 (40.8%)

Class III

27 (55.1%)

  1. *The MD Anderson Cancer Center Residual Cancer Burden Index cannot be calculated in one patient with tumor cells present only in the lymphovascular space
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us